65G:F:F-NEXTCELL PHARMA AB (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.0718

Change

0.00 (0.00)%

Market Cap

USD 8.51M

Volume

1.50K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOVA:F Novo Nordisk A/S

+4.00 (+3.36%)

USD 519.71B
VX1:F Vertex Pharmaceuticals Incorpo..

+5.00 (+1.29%)

USD 101.21B
RGO:F Regeneron Pharmaceuticals Inc

+5.80 (+0.65%)

USD 100.87B
CSJ:F CSL Limited

-0.78 (-0.46%)

USD 81.66B
CSJA:F CSL LTD SPON.ADR 2

-1.00 (-1.17%)

USD 78.61B
0QF:F Moderna Inc

+7.40 (+6.78%)

USD 41.68B
UNC0:F UCB S.A. UNSP.ADR 1/2

+1.50 (+2.54%)

USD 23.00B
UNC:F UCB SA

+4.30 (+3.62%)

USD 22.55B
22UA:F BioNTech SE

-0.40 (-0.47%)

USD 20.71B
1AE:F Argen-X

-4.90 (-1.40%)

USD 20.55B

ETFs Containing 65G:F

ITKY:LSE iShares II Public Limited.. 5.48 % 0.00 %

-31.25 (0.00%)

USD 0.12B
IDTK:LSE iShares MSCI Turkey UCITS 5.40 % 0.00 %

-0.31 (0.00%)

USD 0.12B
IQQ5:F iShares II Public Limited.. 5.40 % 0.00 %

-0.22 (0.00%)

USD 0.10B
IQQ5:XETRA iShares MSCI Turkey UCITS.. 5.40 % 0.00 %

-0.23 (0.00%)

USD 0.10B
HTRY:LSE HSBC MSCI Turkey UCITS ET.. 5.33 % 0.00 %

N/A

USD 0.01B
HTR:PA HSBC ETFs Public Limited .. 5.33 % 0.00 %

N/A

USD 0.01B
H4ZK:F HSBC MSCI Turkey UCITS ET.. 5.33 % 0.00 %

N/A

USD 0.01B
H4ZK:XETRA HSBC MSCI Turkey UCITS ET.. 5.33 % 0.00 %

N/A

USD 0.01B
HTRD:LSE HSBC ETFs Public Limited .. 5.26 % 0.00 %

N/A

USD 0.01B
HTRY:SW HSBC MSCI Turkey UCITS ET.. 5.14 % 0.00 %

N/A

USD 0.50M
TUR iShares MSCI Turkey ETF 3.92 % 0.59 %

-0.68 (0.00%)

USD 0.24B
FEM:LSE First Trust Emerging Mark.. 1.26 % 0.00 %

-1.00 (0.00%)

USD 0.02B
FEMU:LSE First Trust Global Funds .. 1.26 % 0.00 %

+0.13 (+0.00%)

USD 0.02B
FEM First Trust Emerging Mark.. 0.00 % 0.80 %

+0.09 (+0.00%)

USD 0.44B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -63.83% 6% D- 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -63.83% 6% D- 2% F
Trailing 12 Months  
Capital Gain -86.25% 7% C- 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -86.25% 7% C- 3% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -14.23% 26% F 12% F
Dividend Return -14.23% 26% F 11% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.06% 57% F 43% F
Risk Adjusted Return -52.57% 20% F 11% F
Market Capitalization 8.51M 16% F 10% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.